Pro Medicus stock to showcase AI imaging tools at RSNA 2026

Published on 11/13/2026 at 20:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pro Medicus stock is linked to a broader Visage 7 rollout at RSNA 2026. New reporting, pathology and cardiology tools will be demonstrated.

Key points for investors

Visage will present AI-optimized reporting and broader enterprise-imaging capabilities at RSNA 2026.
The presentation covers reporting, digital pathology and cardiology imaging on the Visage 7 platform.
Customer demonstrations and the planned RSNA sessions will provide the next commercial touchpoints.

Pro Medicus, AU000000PME8, Illustration mit AI erstellt.

On November 11, 2026, Visage Imaging, Pro Medicus's wholly owned subsidiary, announced that it will present new Visage 7 capabilities at the Radiological Society of North America meeting from November 29 to December 2 in Chicago. The Financial Times company announcement said the program will focus on AI-optimized reporting and enterprise imaging.

Product rollout and RSNA agenda

Visage 7 Reporting is designed to support radiology workflows with tools including draft-from-prior reporting, revision features, automatic impression generation and error checking. Visage said the reporting module is native to its platform and is intended to reduce reliance on third-party diagnostic reporting systems.

The RSNA demonstration will also cover work-in-progress digital pathology capabilities, including automatic registration, cell counting, fluorescence and Z-stacking. In cardiology imaging, Visage plans to show vascular ultrasound tools and integrations with third-party cardiac reporting systems, including Epic EHR and Epic Cupid.

Customer demonstrations ahead

The company has scheduled a customer presentation on December 1 featuring Myles Taffel of NYU. The session will address automated case distribution and the management of complex clinical workflows. Visage will also present a customer-interview-based whitepaper on the return on investment from next-generation imaging IT and a panel discussion involving Visage 7 users.

For investors, the announcement expands the product narrative beyond picture archiving and communications toward reporting, pathology, cardiology and artificial intelligence on one cloud platform. The commercial significance will depend on how hospitals adopt these modules and translate demonstrations into implementations and recurring contracts.

Pro Medicus stock traded at 125.10 euros on Lang & Schwarz at 20:51 CET on Friday, November 13.